AbbVie Inc. (ABBV)
AbbVie: Dominating Immunology While Building Oncology Upside
None of the Big Pharma players has succeeded in challenging AbbVie's dominance in the immune-mediated inflammatory diseases market. In my view, this is directly related to the near-perfect complementarity of Rinvoq and Skyrizi, spanning indications, routes of administration, and mechanisms of action. The total net revenues of this 'duo' were about $25.87 billion in 2025, up 46.2% from 2024.
Why AbbVie (ABBV) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
3 Dividend Stocks to Hold for the Next 20 Years
AbbVie has demonstrated its ability to successfully navigate change. Coca-Cola will likely soon increase its dividend for the 64th consecutive year.
AbbVie Inc. (ABBV) Presents at Piper Sandler Virtual Novel Targets in Immunology Symposium Transcript
AbbVie Inc. (ABBV) Presents at Piper Sandler Virtual Novel Targets in Immunology Symposium Transcript
54 Stocks, 9 Megatrends: My Favorite Places To Be While Capital Is 'Forced'
My top-down strategy targets 'mission-critical' sectors where capital is forced by secular and cyclical tailwinds—data centers, energy, AI, defense, and infrastructure. AI-driven data center and energy spending, defense modernization, and industrial reshoring are creating robust, non-cyclical investment opportunities across select equities. I highlight actionable picks in each segment, including VRT, VST, QXO, MU, TMO, RTX, RACE, MA, CAT, FCX, and key midstream energy names.
AbbVie sues US health agency over Botox price controls
AbbVie sued the U.S. Department of Health and Human Services on Wednesday, challenging a decision by the Centers for Medicare & Medicaid Services to impose price controls for Botox.
2 Urgent Sells And 2 No Brainer Dividend Buys
One thing I've learned is the pendulum always swings. It is in our best approach to sell high and buy low. This has worked well for us, as our returns suggest.
Here's Why AbbVie (ABBV) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
Here's What Will Drive AbbVie's Top-line Growth in 2026
ABBV sees 2026 revenues rising to $67B as Rinvoq and Skyrizi drive growth, with neuroscience gains offsetting Humira erosion and oncology headwinds.
AbbVie's Prognosis: The February Dip Looks Like a Buy Signal
When the price of a high-quality stock such as AbbVie NYSE: ABBV declines after a report revealing growth, outperformance, and better-than-expected guidance, it's almost always a good time to buy.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
